Natureza was incorporated in 2009 as a US Texas Private Research and Development company. It presently has two anti-infectives in preclinical development. The latest technology has multiple granted US and International Patents and several Patents Pending. Formulations are effective against antibiotic Gram-negative and positive resistant pathogens in the WHO priority list with three agents active against Priority 1 critical pathogens. The group of agents together show proven in vitro activity against 12 of the 15 antibiotic resistant bacteria listed by the WHO as causing the highest levels of concern. Laboratory trials have shown that no resistance has developed to these novel agents during long term repeated exposure, and that no intrinsic resistance can be detected in target pathogens. The agents have a strong safety profile, with GRAS status in the USA. This research was an extension of earlier developments from its affiliate company, BioSafe Technologies, Inc., a US Texas Company incorporated in 2000.
At the time of Natureza’s incorporation, BioSafe Technologies contributed a significant investment in the company for further development and testing of its active ingredient formulations to control endoparasites in humans and animals. The BioSafe management team was contracted by Natureza to assist in the administration procedures and the research activities having Dr. Gerald Coles as a Scientific Advisor. Results from this research in the UK and South America showed activity against endoparasites in addition to the enhancing of the healing of skin wounds, burns and having bacteriostatic properties against gram positive bacteria.
BioSafe Technologies, Inc. developed formulations for pesticide use from natural compounds discovered in South America to control ecto and endoparasites on humans and animals. Results from the UK and South America showed activity against parasites in addition to the enhanced healing of skin wounds, burns and bacteriostatic properties against gram positive bacteria.The latest technology has at least one patent pending.
The company has been manufacturing and exporting a proprietary brand of head lice treatments for over a decade in the US and via several multinational pharmaceutical companies within established brands of children’s products. Business expanded digitally on Amazon.